CLL Video Channel
Explore the latest insights and summaries from experts in CLL.
Recommended for You
Loading...
Trending Videos This Week
Loading...
Treatment Landscape
Danielle Brander
Choosing BTKi or BCL2i or Combination Therapy for 1L CLL
- 715 views
- November 18, 2024
- 4
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: CLL Highlights
FEATURING
Alexey Danilov
- 239 views
- January 15, 2025
- 1
The University of Kansas Cancer Center
Year in Review 2024: CLL Highlights
FEATURING
Marc Hoffmann
- 235 views
- December 27, 2024
- 1
SOHO Brazil 2024
1L Therapy in CLL: What Are the Best Options?
FEATURING
Jan Burger
- 900 views
- July 11, 2024
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Clinical Application of Practice-Changing Abstracts for 1L CLL
FEATURING
Kerry Rogers,
Jennifer Woyach
- 156 views
- February 5, 2025
Moffitt Cancer Center
Emerging Trends in the Treatment Landscape of CLL
FEATURING
Javier Pinilla-Ibarz
- 123 views
- January 21, 2025
- 1
Dima El-Sharkawi
Approach to Treatment Selection and Personalization in 1L CLL
- 110 views
- January 21, 2025
- 1
Nicole Lamanna
Sequencing Therapies in CLL: The Importance of First-Line Treatment Choice
- 274 views
- August 27, 2024
- 3
City of Hope
CLL Treatment Sequencing: The Importance of First Choice
FEATURING
Steven Rosen
- 322 views
- July 3, 2024
Fred Hutchinson Cancer Center
Current Guideline-Informed Treatment of CLL
FEATURING
Chaitra Ujjani
- 95 views
- December 13, 2024
SOHO Brazil 2024
Single vs. Multiple Agents in 2L Therapy for CLL
FEATURING
Jan Burger
- 388 views
- July 11, 2024
- 2
Total Health
Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL, MM, and CLL
FEATURING
Marcello Maria Rotta
- 345 views
- July 8, 2024
2024 ASCO® Annual Meeting Insights Hub
Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and EHA
FEATURING
Kerry Rogers,
Jennifer Woyach
- 325 views
- June 21, 2024
- 1
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Current Options for Finite-Duration Therapy With BTKis in CLL
FEATURING
Ahmad Ibrahim
- 152 views
- August 13, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
State-of-the-Art in CLL Treatment
FEATURING
Antonio Cuneo
- 521 views
- February 16, 2024
- 5
Indy Hematology Review
Treatment Considerations for Initial Therapy of CLL
FEATURING
Peter Hillmen
- 232 views
- April 18, 2024
- 3
UCI Health
Fixed-Duration Treatment in CLL: Current Considerations
FEATURING
Elizabeth Brem
- 708 views
- November 20, 2023
- 2
Insights from 2023 ASH Annual Meeting
The Best of CLL: Highlights & Key Takeaways
FEATURING
Victor Yazbeck
- 625 views
- January 24, 2024
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Overall Survival Outcomes of Real-World Treatment Sequences in CLL/SLL Patients
FEATURING
Joanna Rhodes
- 20 views
- January 21, 2025
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Practical Updates on Advances in CLL and MCL
FEATURING
Elise Chong
- 278 views
- March 13, 2024
- 1
SOHO Highlights: State of the Art and Next Questions
CLL: State of the Art and Next Questions
FEATURING
Nitin Jain
- 272 views
- March 25, 2024
- 1
MyCancerHaven
Conversation With Cancer Experts: Treatment of Double Refractory CLL
FEATURING
Ravi Vij,
Ryan Jacobs
- 35 views
- November 26, 2024
UChicago Medicine
Improving Lymphoma Outcomes: Optimizing Trial Design, Using Surrogate Endpoints, and Incorporating Guidelines
FEATURING
Andrew Zelenetz
- 116 views
- July 22, 2024
- 1
5th SOHO Italy Annual Conference
How I Treat CLL at the MD Anderson Cancer Center
FEATURING
Alessandra Ferrajoli
- 604 views
- November 27, 2023
Adam Kittai
Highlights From iwCLL 2023: What's New and Practice Informing in CLL
- 638 views
- October 13, 2023
- 6
Insights from 2023 ASH Annual Meeting
CLL/SLL: Outcomes of Pts With Richter's Transformation Without Prior Chemoimmunotherapy
FEATURING
Adam Kittai
- 364 views
- December 22, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Current Approach to Sequencing CLL Therapy in the Real World
FEATURING
Gianluca Gaidano
- 403 views
- November 27, 2023
- 2
City of Hope
Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Targeted Strategies
FEATURING
Idoroenyi Amanam
- 219 views
- March 11, 2024
- 1
MyCancerHaven
Conversation With Cancer Experts: Current Treatment of R/R CLL
FEATURING
Ravi Vij,
Marc Hoffmann
- 25 views
- November 26, 2024
Farrukh Awan
Clinical & Non-Clinical Benefits of Fixed-Duration Venetoclax Treatment in CLL
- 40 views
- September 5, 2024
Louisville Hematology Highlights
Current Standard of Care and Future Directions in CLL
FEATURING
Catherine Coombs
- 143 views
- February 26, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
How I Manage Febrile Neutropenia in Patients With Cancer
FEATURING
Şiran Keske
- 74 views
- February 21, 2024
- 1
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Is Finite Duration Therapy the New Standard of Treatment in Frontline CLL?
FEATURING
Alessandra Ferrajoli
- 239 views
- October 6, 2023
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Debates in CLL: The Case for Combination Therapy in 1L
FEATURING
Ahmad Ibrahim
- 39 views
- February 16, 2024
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Manage CLL in Italy
FEATURING
Antonio Cuneo
- 26 views
- November 27, 2023
Therapeutic Agents
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in CLL: Continuous or Finite Duration Therapy
FEATURING
Nitin Jain
- 266 views
- October 6, 2024
Louisville Hematology Highlights
CLL in 2024: Evolution of the Role of Novel Targeted Therapies
FEATURING
Catherine Coombs
- 132 views
- January 10, 2025
- 2
SOHO Brazil 2024
3L in CLL: The Best Options in a Patient Double-Refractory to Covalent BTKi and to BCL-2 Inhibitor
FEATURING
Jan Burger
- 556 views
- July 11, 2024
- 1
MyCancerHaven
The Future of CLL Treatment: Combination Therapies, Overcoming Resistance, and Emerging Strategies
FEATURING
Ravi Vij,
Adam Kittai
- 94 views
- February 14, 2025
Penn Medicine Abramson Cancer Center
Pirtobrutinib Updates in CLL - Considerations for Practice
FEATURING
Jakub Svoboda
- 95 views
- January 8, 2025
- 1
Massachusetts General Hospital Cancer Center
Practice-Changing Updates in Indolent B-Cell Lymphomas
FEATURING
Jake Soumerai
- 520 views
- June 5, 2024
- 1
Nicole Lamanna
Pirtobrutinib in CLL: Current and Potential Utility in the Treatment Landscape
- 111 views
- December 3, 2024
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignancies
FEATURING
Ruemu Birhiray
- 965 views
- April 16, 2024
- 5
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-Cell Malignancies
FEATURING
Mazyar Shadman
- 87 views
- December 18, 2024
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Sonrotoclax + Zanubrutinib in 1L CLL - Results From the BGB-11417-101 Study
FEATURING
Jake Soumerai
- 85 views
- December 20, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Acalabrutinib, Venetoclax, Obinutuzumab in a 1L CLL Enriched for High-Risk Disease
FEATURING
Matthew Davids
- 66 views
- December 13, 2024
City of Hope
Venetoclax vs. BTKis in CLL Treatment
FEATURING
Alexey Danilov
- 265 views
- June 28, 2024
- 1
UChicago Medicine
The Next Frontier of Targeted Therapy in Lymphoma
FEATURING
Kami Maddocks
- 240 views
- July 22, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Patient-Reported QoL Outcomes With Venetoclax-Based 1L Combinations in CLL
FEATURING
Moritz Fürstenau
- 73 views
- January 15, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ibrutinib or Acalabrutinib in CLL - Impact of Dose Reduction on Therapy Duration
FEATURING
Mazyar Shadman
- 66 views
- December 17, 2024
Insights from 2023 ASH Annual Meeting
Treatment Strategies for Hematocrit Control in PV
FEATURING
Amy Zhou
- 954 views
- January 8, 2024
- 6
Avirup Guha
Managing Cardiotoxicities in TKI Therapy for CLL: Atrial Fibrillation and Atrial Flutter
- 85 views
- October 23, 2024
Fox Chase Cancer Center
Pirtobrutinib in R/R B-Cell Malignancies: Newest Data From the BRUIN Trial
FEATURING
Shazia Nakhoda
- 63 views
- December 13, 2024
Lydia Scarfò
Managing Cardiotoxicities in BTKi Treatment for CLL: Atrial Fibrillation and Atrial Flutter
- 97 views
- October 15, 2024
Constantine Tam
R/R CLL: A Matching-Adjusted Indirect Comparison of Zanubrutinib vs. Acalabrutinib
- 317 views
- April 22, 2024
Cleveland Clinic Taussig Cancer Institute
Updates in CLL From ASH 2023
FEATURING
Allison Winter
- 100 views
- October 22, 2024
Saad Kenderian
Liso-Cel in CLL: Summary of FDA Approval and Guidance on Toxicity Management
- 192 views
- July 8, 2024
- 1
Indy Hematology Review
CLL: Evaluating and Therapeutic Approaches for the Management of the R/R Patient
FEATURING
Jennifer Woyach
- 297 views
- April 23, 2024
- 1
MyCancerHaven
CLL and MCL: Experts Discuss the Use of Pirtobrutinib
FEATURING
Ravi Vij,
Geoffrey Shouse
- 241 views
- May 7, 2024
- 2
Manfred Welslau
Ibrutinib for CLL: The Importance of Adherence in Optimizing Efficacy
- 247 views
- May 21, 2024
Insights from 2023 ASH Annual Meeting
Efficacy of Ibrutinib Arms Across ALPINE and ELEVATE-RR Trials in R/R CLL: A Matching-Adjusted Indirect Comparison
FEATURING
Mazyar Shadman
- 824 views
- December 19, 2023
- 1
NYU Langone
Long-Term Efficacy of Ibrutinib in CLL
FEATURING
Marc Braunstein
- 80 views
- October 6, 2024
Daniel Addison
Cardiovascular Considerations With (Contemporary) BTKi in the Treatment of Hematological Malignancies
- 408 views
- February 1, 2024
- 1
City of Hope
Incorporating Pirtobrutinib and CAR-T Therapy Into CLL Practice
FEATURING
Alexey Danilov
- 46 views
- November 12, 2024
University of Colorado Division of Hematology
Summary and Practice Impacts of Recent Updates in B-Cell Lymphomas
FEATURING
Manali Kamdar
- 252 views
- April 8, 2024
- 1
Scripps Health
Updates in CLL: Treatment for BTKi-Refractory and BTKi/BCL-2i-Refractory Disease
FEATURING
Susan O'Brien
- 257 views
- March 18, 2024
Northwestern Medicine Oncology and Hematology
Pirtobrutinib in R/R CLL: Most Recent BRUIN Trial Results
FEATURING
Shuo Ma
- 43 views
- October 29, 2024
Insights from 2023 ASH Annual Meeting
Impact of Ibrutinib Dose Reduction on Duration of Therapy in Patients With CLL/SLL
FEATURING
Mazyar Shadman
- 415 views
- December 19, 2023
- 4
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Advantages of Using Venetoclax-Based Therapy in High-Risk CLL
FEATURING
Catherine Coombs
- 90 views
- June 28, 2024
- 1
MyCancerHaven
Experts Discuss Recent Developments in CLL
FEATURING
Ravi Vij,
Dahlia Sano
- 70 views
- August 30, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Novel Agents in the Treatment of R/R CLL
FEATURING
Nitin Jain
- 45 views
- October 9, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Clinical Application of Practice-Changing Abstracts for R/R CLL
FEATURING
Kerry Rogers,
Jennifer Woyach
- 19 views
- February 5, 2025
UChicago Medicine
Targeting BTK in B-Cell NHL: Pros and Cons of Inhibitors and Degraders
FEATURING
Adam Kittai
- 50 views
- July 22, 2024
- 1
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
CLL: Future Perspectives and Unanswered Questions
FEATURING
Alessandra Ferrajoli
- 218 views
- February 16, 2024
Yale Cancer Center
Yale Cancer Center Updates on B-Cell Lymphomas: Exploring MCL, DLBCL, FL, and CLL/SLL
FEATURING
Shalin Kothari
- 132 views
- May 13, 2024
Insights from 2023 ASH Annual Meeting
Prevalence and Prediction of Ruxolitinib Treatment Emergent Thrombocytopenia in Myelofibrosis
FEATURING
Douglas Tremblay
- 436 views
- December 13, 2023
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ph3 CLL12 Trial - Impact of Ibrutinib on QoL in Pts With Early-Stage, Asymptomatic CLL
FEATURING
Ellinor Goergen
- 17 views
- December 17, 2024
Fred Hutchinson Cancer Center
FDA Approval of Liso-Cel in R/R CLL: What You Need to Know
FEATURING
Mazyar Shadman
- 153 views
- March 26, 2024
Insights from 2023 ASH Annual Meeting
Comparison of Venetoclax Based Treatments for Patients With R/R CLL
FEATURING
Benjamin Heyman
- 296 views
- December 22, 2023
SOHO 2023 Eleventh Annual Meeting
CLL: Next Questions
FEATURING
Nitin Jain
- 454 views
- October 19, 2023
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Venetoclax + Ibrutinib as 1L Treatment in Patients With CLL: Meta-Analysis of RCTs
FEATURING
Ahmet Sarici
- 31 views
- August 15, 2024
Insights from 2023 ASH Annual Meeting
TN-CLL/SLL: Combination Treatment With Sonrotoclax (BGB-11417), a 2nd-Gen BCL2i, and Zanubrutinib
FEATURING
Mary Ann Anderson
- 183 views
- December 14, 2023
Cleveland Clinic Taussig Cancer Institute
R/R CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors
FEATURING
Brian Hill
- 55 views
- June 25, 2024
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Treat CML in 2023
FEATURING
Elias Jabbour
- 154 views
- November 25, 2023
- 2
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Sonrotoclax + Zanubrutinib in R/R CLL/SLL
FEATURING
Stephen S. Opat
- 56 views
- July 3, 2024
Catherine Coombs
Overview of Venetoclax-Obinutuzumab in 1L CLL: Supporting Data and Clinical Pearls
- 7 views
- February 24, 2025
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Effectiveness of Venetoclax-Based Therapy After BTKis in CLL"
FEATURING
Nilanjan Ghosh
- 147 views
- December 17, 2023
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Debates in CLL: The Case for BTKi Monotherapy in 1L
FEATURING
Gerardo Musuraca
- 74 views
- February 16, 2024
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Emerging BCL2 Inhibitors
FEATURING
Mary Ann Anderson
- 139 views
- November 21, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Efficacy of Mosunetuzumab Monotherapy in Patients With R/R Richter's Transformation"
FEATURING
Chan Cheah
- 73 views
- December 20, 2023
ecancer
ASH 2024 Insights: Epcoritamab Monotherapy for Patients With R/R CLL - Updated Results From EPCORE CLL-1 Trial
FEATURING
Alexey Danilov
- 8 views
- January 17, 2025
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "A Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL"
FEATURING
Kerry Rogers
- 70 views
- December 17, 2023
- 1
UChicago Medicine
Exploring the Value of PI3K in Lymphoma Treatment
FEATURING
Changchun Deng
- 19 views
- July 22, 2024
Benjamin Heyman
Venetoclax Consolidation After BTKi Discontinuation for Patients With CLL
- 90 views
- December 4, 2023
SOHO 2023 Eleventh Annual Meeting
Liso-Cel in R/R CLL/SLL: Primary Analysis of the Phase 1/2, Single-Arm, Multicenter TRANSCEND CLL 004 Study
FEATURING
Tanya Siddiqi
- 116 views
- October 10, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Anti-CD19 CAR T-Cell Therapy for Richter's Transformation"
FEATURING
Adam Kittai
- 55 views
- December 22, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: How to Improve the Use Novel Agents in Elderly Patients With CLL
FEATURING
Ahmad Ibrahim
- 75 views
- November 27, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Debate: MRD+ After 1 Year of VenG in CLL - Stop or Continue Therapy?
FEATURING
Othman Al-Sawaf,
Nicole Lamanna
- 74 views
- October 6, 2023
City of Hope
Primary Analysis of TRANSCEND CLL 004 - Liso-Cel in R/R CLL/SLL
FEATURING
Tanya Siddiqi
- 50 views
- November 6, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "A Long-Term Analysis of Lenalidomide & Rituximab for the Treatment of CLL"
FEATURING
Chung-Jiah Chen
- 31 views
- December 17, 2023
Arnon Kater
iwCLL Insights: "EPCORE CLL-1 Trial - Epcoritamab in Patients With R/R CLL"
- 31 views
- December 4, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: How We Developed a Curative Therapy for CLL and Stopped Using It
FEATURING
John Seymour
- 20 views
- October 9, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: CAR T-Cell Therapy for CLL - A New Addition to our Treatment Toolbox?
FEATURING
Lorenzo Lovino
- 13 views
- November 27, 2023
Oncology Data Advisor
Epcoritamab in R/R CLL: Insights From the EPCORE CLL-1 Trial
FEATURING
Alexey Danilov
- 10 views
- February 14, 2025
Diagnostics & Biomarkers
UChicago Medicine
Debates in CLL: Measuring MRD is NOT the SOC
FEATURING
Jacob Soumerai
- 209 views
- July 22, 2024
- 2
Richard Rosenquist Brandell
Realizing Precision Medicine in CLL: Remaining Challenges and Potential Opportunities
- 72 views
- October 17, 2024
- 1
MyCancerHaven
Evolving Concepts in CLL: Incorporating MRD
FEATURING
Ravi Vij,
Danielle Brander
- 164 views
- August 30, 2024
UChicago Medicine
Debates in CLL: MRD Measurement in Fixed Duration Venetoclax-Based Therapy is SOC
FEATURING
Joanna Rhodes
- 75 views
- July 22, 2024
- 2
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Primetime?"
FEATURING
Joanna Rhodes
- 330 views
- December 22, 2023
- 2
ecancer
EHA 2024 Insights: Only Certain TP53 Mutations are Prognostic for PFS and OS in CLL
FEATURING
Consuelo Bertossi
- 56 views
- July 23, 2024
- 1
Insights from 2023 ASH Annual Meeting
Zanubrutinib in 1L CLL: A Biomarker Analysis From the Phase 3 SEQUOIA Study
FEATURING
Paolo Ghia
- 117 views
- March 27, 2024
5th SOHO Italy Annual Conference
Monitoring & MRD in CLL: When and Why?
FEATURING
Massimo Massaia
- 96 views
- November 27, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: How Biologic Markers Impact CLL Outcomes With Novel Therapy
FEATURING
Talha Munir
- 67 views
- October 18, 2023
University of Colorado Division of Hematology
Overview of Physical Exams, Labs and Diagnostic Testing for Blood Cancer Patients
FEATURING
Meredith Beaton
- 31 views
- October 24, 2023
Disease Overview
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
FEATURING
Robert Peter Gale
- 4,555 views
- February 26, 2024
- 21
Yale Cancer Center
Caring for Patients With Lymphoma: Using Guidelines to Improve Quality of Care
FEATURING
Scott Huntington,
Eric Winer
- 81 views
- September 11, 2024
Masonic Cancer Center, University of Minnesota
Blood Cancers Basics
FEATURING
Zohar Sachs
- 37 views
- October 7, 2024
Brian Koffman
Supporting Patients With CLL: Highlighting the Importance of Community
- 32 views
- November 1, 2024
Yale Cancer Center
CLL: Genotype to Phenotype and Beyond
FEATURING
Catherine Wu
- 266 views
- February 12, 2024
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Clinical Significance of MBL
FEATURING
Sameer Parikh
- 19 views
- October 18, 2023
Case Studies
XV Eurasian Hematology-Oncology Congress - EHOC 2024
CLL Case Discussion: First Line Treatment Strategies
FEATURING
Damla Ortaboz
- 74 views
- September 6, 2024
Yale Cancer Center
Case-Based Discussions in Lymphoma: 1L MCL, CD30+ T-Cell, and R/R CLL
- 101 views
- May 14, 2024
Moffitt Cancer Center
Optimal Management of Patients With CLL in 2024: Interactive Cases Discussion
FEATURING
Javier Pinilla-Ibarz
- 160 views
- March 4, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
CLL Case Discussion: Diagnosis and Managment of Richter Syndrome
FEATURING
Mohammed Kamil Al Qayyim
- 18 views
- October 15, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
CLL Case: Acquired Del(17p) at Relapse
FEATURING
Melis Dila Özer Çerme
- 13 views
- October 15, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
MPN Case Discussion: ET With Coincindent CLL
FEATURING
Giuseppe Saglio
- 13 views
- September 27, 2024
PrecisCa
Expert Panel Case Discussion: 64 y/o Male With a History of CLL Presents With Thrombocytopenia
- 101 views
- December 4, 2023
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
CLL Case Presentation: 72 y/o Male With Cardiac Comorbidities
FEATURING
Fatma Eda Nuhoğlu Kantarcı
- 16 views
- February 16, 2024
